Sun Pharma eyes high single-digit top-line growth in FY23

"We expect high single-digit top-line growth for FY23. All our businesses are positioned for growth. Ramp up in our global speciality business is expected to continue," Sun Pharma Managing Director Dilip Shanghvi said in an analyst call.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2YSl4In
via IFTTT